Full-Time

Benefits & Total Rewards Director

Updated on 9/4/2026

Umoja Biopharma

Umoja Biopharma

201-500 employees

In vivo CAR T-cell cancer therapy

Compensation Overview

$194.8k - $240.7k/yr

Seattle, WA, USA + 1 more

More locations: Lafayette, CO, USA

Hybrid

Two days on-site per week in Seattle; travel to Colorado site as needed.

Bachelor's

Category
People & HR (1)
Required Skills
Forecasting
Workday HRIS
SAP Products
Human Resources Information System (HRIS)
Data Analysis

Get referred to Umoja Biopharma

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Human Resources, Business Administration, Finance, or a related field.
  • 10+ years of progressive experience in Total Rewards, with significant depth in benefits strategy, administration, and compliance.
  • 3+ years of functional leadership experience; meaning owning Benefits function or related department
  • Deep knowledge of health and welfare plans, retirement plans, leave administration, open enrollment, benefits operations, and benefits compliance requirements.
  • Demonstrated experience working with benefits brokers, carriers, consultants, and third-party administrators.
  • Experience leading annual renewals, plan design evaluations, vendor negotiations, and employee communications.
  • Proven ability to use data and market insights to make strategic recommendations.
  • Experience navigating applicable benefits regulations, including ERISA, COBRA, ACA, HIPAA, and leave-related requirements.
  • Experience with HRIS and benefits administration platforms such as UKG, Workday, ADP, SAP, Paylocity, or similar systems.
Responsibilities
  • Lead the strategy, design, implementation, and ongoing administration of the company’s health and welfare programs, including medical, dental, vision, life and disability insurance, retirement plans, leave programs, wellness initiatives, and other employee benefits.
  • Develop and evolve a forward-looking benefits strategy that supports talent attraction, retention, employee wellbeing, and organizational scalability.
  • Assess current programs and recommend enhancements based on business needs, employee feedback, utilization trends, benchmarking, and cost considerations.
  • Partner with leadership to define a long-term benefits philosophy that aligns with the company’s values, growth plans, and total rewards strategy.
  • Evaluate the competitiveness and effectiveness of benefit offerings relative to market practice, with an eye toward balancing employee experience with fiscal responsibility.
  • Oversee all aspects of day-to-day benefits administration, including enrollments, life event changes, eligibility, plan changes, claims escalations, and employee communications.
  • Ensure accurate and timely coordination of benefits processes with Payroll, HRIS, HR Operations, and external administrators.
  • Lead annual open enrollment strategy and execution, including plan design recommendations, employee communications, education sessions, systems testing, and issue resolution.
  • Manage and optimize benefits administration processes, systems, workflows, and controls to improve efficiency, compliance, and service delivery.
  • Monitor benefit plan utilization, employee inquiries, and vendor performance to identify opportunities for process improvement and enhanced employee support.
  • Serve as the primary relationship owner for benefits brokers, carriers, consultants, and third-party administrators.
  • Lead vendor selection, renewal negotiations, performance reviews, service issue escalation, and contract management.
  • Partner with brokers and consultants on annual renewals, plan design analysis, benchmarking, and cost-containment opportunities.
  • Ensure vendors deliver high-quality service, accurate administration, and actionable reporting and insights.
  • Oversee compliance with applicable federal, state, and local laws and regulations related to employee benefits, including but not limited to ERISA, COBRA, ACA, HIPAA, FMLA, Colorado FAMLI, WA PFML, Section 125, and other applicable leave and benefits regulations.
  • Partner with Legal and external advisors to ensure plan documents, SPDs, notices, filings, and communications are timely, accurate, and compliant.
  • Support plan audits, nondiscrimination testing, annual filings, and other compliance-related activities.
  • Develop and maintain internal controls, plan administration documentation, and standard operating procedures to reduce risk and improve consistency.
  • Stay current on legislative and regulatory developments that may affect benefit programs and recommend proactive changes as needed.
  • Create and execute a thoughtful employee communication strategy for benefits that improves awareness, understanding, and appreciation of the company’s offerings.
  • Translate complex benefits information into clear, employee-friendly materials and decision support tools.
  • Partner with VP, HR and managers to support employee education and engagement with benefits and wellbeing programs.
  • Address escalated employee issues with empathy, responsiveness, and sound judgment.
  • Contribute to the development and administration of the company’s broader total rewards strategy, including compensation programs, recognition initiatives, and rewards communications, as needed.
  • Partner with HR leadership and Finance on rewards-related budgeting, planning, and forecasting.
  • Support market benchmarking and competitive analysis for rewards programs to ensure alignment with business strategy and talent needs.
  • Provide recommendations and insights on total rewards trends, employee value proposition, and program effectiveness.
  • Analyze benefits plan performance, enrollment trends, costs, and utilization data to inform strategic recommendations.
  • Develop dashboards, reports, and presentations for leadership on program performance, renewal strategies, employee participation, and cost drivers.
  • Use data and employee feedback to guide continuous improvement efforts and measure program impact.
Desired Qualifications
  • Experience in a high-growth organization; biotechnology, life sciences, healthcare, or other regulated environment preferred.
  • Excellent communication and interpersonal skills, with the ability to explain complex information clearly to employees and leaders.
  • High attention to detail, sound judgment, and a commitment to confidentiality.
  • Strong project management, organizational, and operational execution skills.
  • Experience with various state leave laws and requirements
  • Experience supporting a multi-state workforce.
  • Familiarity with compensation principles and broader total rewards program design.
  • CCP, CEBS, CBP, or similar professional certification.
  • Knowledge of survey management and benchmarking tools
  • Experience managing equity programs for public and private companies

Umoja Biopharma develops immunotherapies that reprogram patients’ T cells inside the body (in vivo) to attack cancer. Its main product approach is a CAR T-cell gene therapy platform designed to be produced in-house and sold as off-the-shelf regimens, enabling scalable treatment for both solid tumors and blood cancers that have not responded to other therapies. The treatment works by modifying the patient’s immune system directly in the body to create CAR T cells that can target and kill cancer cells, aiming for lasting remissions. Unlike many therapies that extract cells from a patient, modify them outside the body, and then reinsert them, Umoja Biopharma focuses on in-body cell reprogramming and in-house manufacturing to streamline delivery. The company differentiates itself through its in vivo, off-the-shelf CAR T approach and its goal of broad applicability across cancer stages, seeking to provide accessible, scalable cancer treatments across solid and hematologic cancers.

Company Size

201-500

Company Stage

Series C

Total Funding

$363M

Headquarters

Seattle, Washington

Founded

2019

Get referred to Umoja Biopharma

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA cleared UB-VV400 in July 2026; first patient dosing targets Q3 2026.
  • In January 2025, Umoja closed a $100 million Series C led by Double Point Ventures and DCVC Bio.
  • March 2026 board additions Marcela Maus and Athena Countouriotis strengthen clinical and commercial credibility.

What critics are saying

  • UB-VV400 still lacks patient data; VIBRANT-1 starts in 2026 and answers remain years away.
  • Umoja depends on lentiviral delivery; manufacturing failures in Louisville would stall every VivoVec program.
  • Interius, Allogene, and Vyriad are racing in vivo CAR-T; one cleaner dataset can commoditize Umoja's platform.

What makes Umoja Biopharma unique

  • Umoja's VivoVec platform generates CAR T cells inside patients, avoiding ex vivo manufacturing.
  • UB-VV400 became the industry's first known CD22-directed in vivo CAR T IND on July 16, 2026.
  • UB-VV500 adds dual BCMA-GPRC5D targeting for multiple myeloma, extending platform breadth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Phone/Internet Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-3%
Yahoo Finance
Mar 23rd, 2026
Umoja Biopharma appoints Dr Marcela Maus and Dr Athena Countouriotis to board of directors

Umoja Biopharma, a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, has appointed Dr Marcela Maus and Dr Athena Countouriotis to its board of directors. Dr Maus is a professor of medicine at Harvard Medical School and director of cellular immunotherapy at Massachusetts General Hospital. She is internationally recognised in immunology and T cell-based cancer therapies, having authored over 200 publications. Dr Countouriotis is co-founder, president and chief executive officer of Avenzo Therapeutics. She previously led Turning Point Therapeutics from IPO to acquisition in 2022 and has over 20 years of industry experience. The appointments will support Umoja's VivoVec platform, which generates CAR T cells directly in the body, aiming to simplify delivery and expand access to transformative cancer therapies.

Umoja Biopharma
Mar 6th, 2026
Umoja Biopharma Honors the Life and Legacy of Scientific Co-founder Dr. Philip Low

Umoja Biopharma honors the life and legacy of scientific co-founder Dr. Philip Low. SEATTLE, WA, March 6, 2026 - Umoja Biopharma announces with deep sadness the passing of Dr. Philip Low, a pioneering scientist, entrepreneur, and one of its scientific co-founders, whose career reflected a lifelong commitment to translating innovative science into patient impact. Dr. Low passed away this week at the age of 78, leaving behind an extraordinary legacy in drug discovery and development, including Umoja's first clinical-stage program built on his foundational work at Purdue University. "Phil was a once-in-a-generation scientist whose work fundamentally reshaped our understanding of how CAR T cells can and should work in the body," said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma. "He brought not only extraordinary intellectual rigor to Umoja's early days, but a deep conviction that novel, groundbreaking science must ultimately serve patients. We are profoundly grateful for his scientific leadership and mentorship. Phil was a great friend and colleague. My thoughts are with his family, friends, and colleagues at Purdue." Over nearly five decades at Purdue University, Dr. Low became one of the world's most influential scientists in academic drug discovery. He joined Dr. Andrew Scharenberg and Dr. Ryan Crisman in the founding of Umoja Biopharma in 2019. Dr. Low's work was fundamental in the discovery and development of Umoja's early scientific exploration in solid tumors, including its TumorTag programs and Phase I ENLIGHTen clinical trial in partnership with Seattle Children's Research Institute. About Umoja Biopharma Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. Umoja's VivoVec(TM) in vivo gene delivery technology empowers a patient's own immune system to fight disease. Enabling its core technology is the Company's state- of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit umoja-biopharma.com.

GeekWire
Mar 18th, 2025
Geekwire Awards: Health Innovation Of The Year Field Is Dominated By Finalists Battling Cancer

The 2025 GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with groundbreaking new technologies. The contenders range from a newly formed startup to a leading U.S. cancer institute and companies in between. Joining the cohort is a business with technology to help healthcare providers better manage appointments and access to providers.This awards category recognizes pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for improving peoples’ lives and enhancing the healthcare system.The finalists are Archon Biosciences, DexCare, Fred Hutch Cancer Center, Talus Bioscience and Umoja Biopharma.Last year’s winner was CalmWave, a Seattle health-tech startup that created a system for making sense of the alarms triggered by the devices that monitor hospital ICU patients.Continue reading for details on each of this year’s finalists, and vote here or below.Archon BiosciencesArchon Biosciences emerged from stealth last October with $20 million in funding. The Seattle biotech company is running with technology developed in the lab of University of Washington biochemist and Nobel Prize winner David Baker.Archon’s proprietary protein structures, known as Antibody Cages or AbCs, combine two biomedical tools — naturally occurring antibodies and custom-designed proteins — to create a single new protein structure. These protein structures, or AbCs, are optimized with the aid of generative AI to travel in the body in controllable ways and engage with target cells in a more specific manner.“What we like to say is, it’s not whether you’re given a drug, it’s how you’re given it,” said CEO and co-founder James Lazarovits

GeekWire
Mar 4th, 2025
Tech Moves: Starbucks Names Cfo; Avanade Bolsters C-Suite; Tune Therapeutics Gets Ceo

Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected] Smith, CFO of Starbucks. (LinkedIn Photo)— Starbucks announced Cathy Smith as its chief financial officer. Smith was most recently at Nordstrom for two years, and has held CFO roles at Bright Health, Target, Express Scripts, Walmart and others. Her longest role was at the defense and space juggernaut Raytheon.Smith succeeds Rachel Ruggeri, who was at Starbucks for more than two decades, ascending to the CFO role in 2021.The coffee giant announced layoffs of 1,100 corporate employees, including 612 in Seattle. It marks one of Starbucks’ largest layoffs and comes as CEO Brian Niccol turns to tech to help turn around the slumping business after taking over in September.— Avanade, a Seattle-based tech consulting and services company, announced a slate of C-suite hires

Benzinga
Jan 14th, 2025
Umoja Biopharma Raises $100M Series C

Umoja Biopharma announced a $100 million Series C financing to advance its in vivo CAR T cell therapy pipeline. The round was co-led by Double Point Ventures and DCVC Bio, with participation from investors like ARK Invest and SoftBank Vision Fund 2. The funds will support clinical development, including the lead CD22 UB-VV400 program. Campbell Murray, M.D., joins the Board of Directors. This financing highlights Umoja's potential to innovate in oncology and autoimmune treatments.